. [eighty two] to assess the efficacy, security and tolerability of Cannabidiol being an adjunct therapy coupled with anti-epileptic medicine around the sufferers suffering from tuberous sclerosis complicated whose most typical neurological symptom is epilepsy. On this scientific demo study, rig